Skip to main content

Home›Research›Compare›CJC-1295 DAC vs Sermorelin

Peptide Comparison

CJC-1295 DAC vs Sermorelin

Both are GH / IGF Axis peptides.

CJC-1295 DAC

CJC-1295 with DAC

Fat LossNot EvaluatedResearch Only

Half-life: 6–8 days

13 providers listed

Full CJC-1295 DAC profile →
vs

Sermorelin

GHRH 1-29

PerformanceUnder clinical reviewPrescription

Half-life: 10–20 minutes

469 providers listed

Full Sermorelin profile →
Bottom line

CJC-1295 DAC has a longer half-life than Sermorelin, so it generally needs less frequent dosing.

Quick Verdict

CJC-1295 DAC

Half-life

6–8 days

Sermorelin

Half-life

10–20 minutes

Which One Should You Choose?
Your goalBetter option
Stronger clinical evidenceSermorelin
Less frequent dosing (longer half-life)CJC-1295 DAC
Lower typical price per mgSermorelin
More provider options (13 vs 469)Sermorelin

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison
CJC-1295 DAC
Sermorelin
Mechanism Family
GH / IGF Axis
GH / IGF Axis
Half-life
6–8 days
10–20 minutes
FDA Status
not evaluated
Under clinical review
Admin Routes
subcutaneous
subcutaneous
Availability
Research Only
Prescription
Providers
13 listed
469 listed
Avail. Notes
Long-acting GHRH analog with a Drug Affinity Complex (DAC) modification. No FDA approval. Not on the FDA 503A bulks list. WADA-prohibited as a growth hormone releasing factor. Sold as a research chemical only.
Previously FDA-approved for pediatric GH deficiency (Geref); approval withdrawn 2008. Its bulk substance appears on the FDA 503B outsourcing-facility list (Category 1) but not the 503A pharmacy bulk-substances list; compounded-product availability historically rested on the former approved-drug status.
Research Evidence

CJC-1295 DAC

RCT · 1 key study · dated evidence base — most recent 2006

Sermorelin

RCT · 3 key studies · most recent 2026
Research Citations

About CJC-1295 DAC

CJC-1295 DAC is a GHRH analog carrying a Drug Affinity Complex (DAC) modification that binds covalently to circulating albumin, greatly extending its plasma half-life relative to unmodified or short-acting GHRH analogs. Through this albumin binding it acts as a long-lasting agonist at pituitary GHRH receptors, associated in research with sustained growth hormone and downstream IGF-1 elevation. This contrasts with the non-DAC form (Mod GRF 1-29), whose action is measured in minutes rather than days.

Research Areas
GH and IGF-1 elevation studied in a single-dose human PK trialsustained GHRH-receptor agonism via albumin bindingextended plasma half-life relative to short-acting GHRH analogsbody-composition and GH-axis research contextssubcutaneous administration in published research

About Sermorelin

Sermorelin is a synthetic analogue of the first 29 amino acids of endogenous growth hormone-releasing hormone (GHRH). It binds to GHRH receptors on pituitary somatotrophs, stimulating pulsatile GH secretion in a physiological pattern that preserves the natural hypothalamic-pituitary feedback axis — contrasting with direct GH administration. Downstream IGF-1 elevation mediates many of its body composition, tissue-repair, and sleep quality effects.

Research Areas
pulsatile GH release via direct GHRH receptor agonism at the pituitaryendogenous GH axis restoration — preserves natural pulse patterns unlike exogenous GHlean mass, sleep quality, and metabolic improvements in anti-aging clinical researchsubcutaneous injection — widely available through telehealth anti-aging providers
Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

CJC-1295 DAC

Warnings & Cautions
Active malignancy — caution (GH/IGF-1 is mitogenic)Pregnancy — cautionKnown hypersensitivityGlucose intolerance / insulin resistance

Class-based (investigational)

Suggested Monitoring
IGF-1Fasting glucoseHbA1cInsulin

Research protocols routinely measure IGF-1 to track GH axis activity before and during use. Fasting glucose and insulin are monitored because GH elevation can reduce insulin sensitivity over time.

Regulatory Notes

global — WADA

This compound falls under WADA Prohibited List category S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), prohibited at all times for competing athletes.

source

Sermorelin

Absolute Contraindications

Under clinical review

Being verified by our medical team before we display contraindications for this peptide.

Suggested Monitoring
IGF-1Fasting glucoseHbA1cInsulin

Sermorelin clinical protocols measure IGF-1 as the primary marker of GH axis response. Fasting glucose and insulin are standard baseline assessments given GH's effect on insulin sensitivity.

Used Together?

Sermorelin

  • Ipamorelin

    Research suggests Sermorelin and Ipamorelin may produce complementary growth hormone release effects when combined. Sermorelin acts as a GHRH analogue via pituitary receptors, while Ipamorelin acts via ghrelin receptors — dual-pathway stimulation studied in GH optimization research.

Price (per mg)

CJC-1295 DAC

$11.24/mg

$8.55 – $17.68 range

25 vendors

Sermorelin

$8.62/mg

$6.88 – $10.85 range

62 vendors

Find Providers

Where to source these peptides

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More GH / IGF Axis Comparisons

Browse all peptides →

Educational research tools — not medical advice.

Cite this page

Data last updated September 28, 2026

Free to reference and republish with attribution to PeptideBase. Choose a format:

PeptideBase. (2026). CJC-1295 DAC vs Sermorelin — Per-mg Price Comparison. Retrieved October 15, 2026, from https://peptidebase.io/peptides/compare/cjc-1295-dac/sermorelin

Free newsletter

The Peptide Research Digest

Weekly analysis on providers, sourcing and compounds — from the team behind PeptideBase.

No spam. Unsubscribe anytime. Privacy policy.